WASHINGTON — President Trump is broadly anticipated to attempt to advance a “most-favored nation” coverage subsequent week in an effort to scale back U.S. drug costs — a transfer that’s prone to considerably rattle the pharmaceutical business, cheer his political base, and, presumably, depart open some very massive questions.
The thought behind the coverage, typically talking, is straightforward: It might tie funds for medicine in the USA to costs paid by different high-income international locations, a lot of which pay far lower than Individuals for his or her medicines. It’s additionally not a brand new concept: The primary Trump administration tried to set it in movement, just for its plans to be blocked.
However now, having discovered the teachings from that defeat, and with a majority within the Home and the Senate, the administration might face higher odds.
This text is unique to STAT+ subscribers
Unlock this text — plus day by day intelligence on Capitol Hill and the life sciences business — by subscribing to STAT+.
Have already got an account? Log in
View All Plans